Creative Medical Technology Holdings, INC

Creative Medical Technology Holdings' stockholders approved the full exercise of warrants for 2.79 million common shares at a recent Special Meeting.

Creative Medical Technology Holdings, Inc. announced the results of its 2025 Annual Meeting of Stockholders, where all director nominees were elected, executive compensation was approved, and Haynie & Company was ratified as independent accountants.

Creative Medical Technology Holdings, Inc. announced its Compensation Committee approved bonuses for its CEO and CFO totaling $125,000.

Creative Medical Technology Holdings, Inc. raised approximately $4.2 million by inducing existing warrant holders to exercise their warrants, issuing new warrants as an incentive.

Creative Medical Technology Holdings' stockholders approved the full exercise of warrants to purchase 1,799,774 shares of common stock at a special meeting held on May 5, 2025.

Creative Medical Technology Holdings received a letter from Nasdaq regarding a delay in adopting and disclosing its Clawback Policy, but Nasdaq has since confirmed the company is now in compliance and the matter is closed.

Creative Medical Technology Holdings reports a net loss of $1.4 million for Q1 2026 as it continues to advance its regenerative medicine clinical pipeline.

Creative Medical Technology Holdings, Inc. reported an increased net loss for the nine months ended September 30, 2025, despite significant clinical trial advancements and successful capital raises through warrant exercises.

Creative Medical Technology Holdings, Inc. reported an increased net loss for Q2 2025 despite significant clinical trial advancements and a successful warrant exercise raising $3.7 million.

Creative Medical Technology Holdings reports its financial results for the first quarter of 2025, highlighting revenue generation, increased R&D spending, and proceeds from warrant exercises.

Creative Medical Technology Holdings reports a net loss of $1.04 million for the third quarter of 2024, while progressing its clinical trials and research programs.

Creative Medical Technology Holdings reports a net loss of $1.56 million for the second quarter of 2024, with a slight increase in revenue and a significant rise in research and development expenses.

Creative Medical Technology Holdings files an amendment to its 2025 Annual Report, detailing executive compensation, governance, and related-party transactions.

Creative Medical Technology Holdings, Inc. reported increased net losses for 2025 despite significant clinical trial advancements and successful capital raises, highlighting ongoing R&D investment.

Creative Medical Technology Holdings files an amendment to its 2024 annual report, providing updates on executive compensation, director information, related party transactions, and other corporate governance matters.

Creative Medical Technology Holdings files an amendment to its annual report to include a clawback policy in compliance with Nasdaq listing rules.

Creative Medical Technology Holdings files an amendment to its annual report to correct the number of outstanding shares and the date of the independent auditor's report.

Creative Medical Technology Holdings reports its financial results for the year ended December 31, 2024, and provides updates on its clinical programs and pipeline development.

Michael H. Finger, a director of Creative Medical Technology Holdings, Inc., sold a total of 1,500 shares of common stock in two transactions on February 18 and 19, 2025.

Creative Medical Technology Holdings, Inc. is holding a special meeting on August 28, 2026, to vote on increasing authorized shares and approving the exercise of investor warrants.

Creative Medical Technology Holdings, Inc. is holding a Special Meeting on December 26, 2025, to seek stockholder approval for the full exercise of warrants covering 2,790,340 shares of common stock.

Creative Medical Technology Holdings, Inc. announced its 2025 Annual Meeting of Stockholders to be held on December 18, 2025, to vote on director elections, executive compensation, and auditor ratification.

Creative Medical Technology Holdings is holding a special meeting on May 5, 2025, to seek stockholder approval for the exercise of warrants covering 1,799,774 shares of common stock to comply with Nasdaq Listing Rule 5635(d).

Creative Medical Technology Holdings is holding a special meeting to seek stockholder approval for increasing authorized shares and approving the exercise of investor warrants.

Creative Medical Technology Holdings is holding its 2024 Annual Meeting of Stockholders on July 19, 2024, to vote on key proposals including increasing authorized shares, electing directors, and ratifying executive compensation.

Creative Medical Technology Holdings, Inc. has filed an S-1/A registration statement for a best-efforts public offering of common stock and warrants to raise approximately $5.34 million.

Creative Medical Technology Holdings, Inc. has filed a registration statement for a best-efforts public offering of common stock and warrants to raise approximately $5.34 million in net proceeds.

Creative Medical Technology Holdings has filed a registration statement for the potential resale of up to 837,104 shares of its common stock by selling stockholders.

Armistice Capital, LLC and Steven Boyd have reported a 4.99% beneficial ownership stake in Creative Medical Technology Holdings, Inc. through a Schedule 13G filing.

Armistice Capital, LLC and Steven Boyd have jointly disclosed a beneficial ownership of 148,000 shares, representing 5.72% of Creative Medical Technology Holdings, Inc.'s common stock.